Abingworth brings in new leadership
This article was originally published in Clinica
Executive Summary
Abingworth, the international investment group focused on healthcare and life sciences, has appointed Tim Haines and Kurt von Emster joint managing partners. They succeed Stephen Bunting, who takes on the role of chairman. Mr Haines, who is based in London, has been with Abingworth since 2005, while Mr von Emster, based in California, joined the firm in January this year. Mr Bunting commented that the “new and younger leadership will build on all that has been achieved to date with new insights and energy”. Abingworth has funds under management of voer $1.25bn. Its medtech investments in its latest Bioventures VI fund include corneal crosslinking specialist Avedro and medical imaging company Median Technologies. Other medtech companies in Abingworth’s portfolio have included, among others, Lombard Medical and Epigenomics, who both went public, and Pathwork Diagnostics, which was acquired by Response Genetics.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.